Business, energy, technology, markets and global industry news from Business News Today

Suzhou Ribo Life Science

PharmaDeviceNews Suzhou Ribo Life Science
Ribo and Madrigal have advanced their first siRNA drug candidate for MASH into IND-enabling studies, highlighting the growing role of gene-silencing therapies in liver disease treatment. Representative image.
Pharma & Biotech

Madrigal expands MASH strategy as first Ribo siRNA candidate enters IND preparation

Discover why Ribo and Madrigal’s first nominated siRNA candidate could reshape genetically targeted and combination treatment strategies in MASH.

Read More
Representative image of cardiovascular drug research and RNA-based therapeutic development. Ribo’s RBD1119 Phase 2 filing highlights growing interest in siRNA antithrombotic strategies for coronary artery disease.
Pharma & Biotech

Ribo’s coronary artery disease filing highlights the next frontier for RNA-based cardiovascular drugs

Ribo’s RBD1119 Phase 2 filing could test whether siRNA drugs can reduce coronary artery disease risk without bleeding trade-offs.

Read More